Castle Biosciences CSTL made its public debut Thursday morning, opening at $20 after being priced at $16 per share.
The shares of the company have been listed on the Nasdaq under the ticker symbol CSTL.
See Also: Castle Biosciences IPO: What You Need To Know
Castle is a commercial-stage dermatological cancer company that provides physicians and their patients personalized, clinically actionable genomic information to make more accurate treatment decisions.
SVB Leerink and Baird are the joint book-running managers for the offering, while Canaccord Genuity and BTIG are co-managers.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
